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Abstract 
Background: Chlamydia pneumoniae and Mycoplasma pneumoniae have been implicated in the pathogenesis of 
asthma and are responsible for chronic inflammation when host immune system fails to eradicate the bacteria.
Method: We performed a prospective study on 410 patients who underwent a visit at the asthma clinic of CHU of 
Liege between June 2016 and June 2018 with serology testing for C. pneumoniae and M. pneumoniae.
Results: 65% of our asthmatic population had serum IgA and/or IgG towards C. pneumoniae, while only 12.6% 
had IgM and/or IgG against M. pneumoniae. Compared to seronegative asthmatics, asthmatics with IgA+ and 
IgG+ against C. pneumoniae were more often male and older with a higher proportion of patients with smoking 
history. They received higher doses of inhaled corticosteroids (ICS) and displayed lower  FEV1/FVC ratio, higher RV/
TLC ratio and lower conductance. They had higher levels of fibrinogen, though in the normal range and had lower 
sputum eosinophil counts. Patients with IgA− and IgG+ against C. pneumoniae were older and had higher blood 
monocyte counts and alpha-1-antitrypsin levels as compared to seronegative patients. Patients with IgM and/or 
IgG towards M. pneumoniae were more often males than seronegative asthmatics. In a subpopulation of 14 neutro-
philic asthmatics with Chlamydia pneumoniae IgA + /IgG + treated with macrolides, we found a significant decrease 
in blood neutrophils and normalization of sputum neutrophil count but no effect on asthma quality of life and 
exacerbations.
Conclusion: Positive Chlamydia serologic test is more common than positive Mycoplasma serology. Asthmatics with 
IgA and IgG against C. pneumoniae have more severe disease with increased airway obstruction, higher doses of ICS, 
more signs of air trapping and less type-2 inflammation.
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Introduction
Asthma is an inflammatory disease of the airways that 
is characterized by airway hyperresponsiveness towards 
various environmental factors. Previous studies suggest 
that the respiratory tract microbiome may underlie the 
development of asthma [1] and clinical studies report 
that up to 45% of adult-onset asthma starts after acute 
respiratory illness [2, 3].
Chlamydia pneumoniae and Mycoplasma pneumoniae 
are intracellular and extracellular bacteria respectively, 
both causing respiratory tract infection. Chlamydia and 
Mycoplasma pneumoniae have been implicated in the 
pathogenesis [4] of asthma [5–7], especially adult onset 
asthma [8]. Chlamydia pneumoniae is thought to pro-
mote asthma by inducing both airway eosinophilia and 
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neutrophilia with concomitant enhancement of the 
severity of airways disease [9] and asthma symptoms 
[10]. Failure to eradicate  C. pneumoniae  can lead to 
chronic infection, where C. pneumoniae enters a state of 
“latency” in which it is viable but dormant and does not 
multiply. It however continues to synthetize heat shock 
protein 60 [11], able to induce a strong inflammatory 
response and may have intermittent periods of replica-
tion. In a study looking at asthmatics and non-asthmatic 
controls, C. pneumoniae led to an increase of IgE, IL-4 
and IFN-gamma in asthmatics as compared to non-
asthmatics [12]. Chlamydia pneumoniae has also been 
shown to induce secretion of TNF-alpha and IL-8 [13]. 
It has been suspected to contribute to airway remodeling 
[14] by inducing the production of IL-6, IFN-Beta and 
MMPs that can promote smooth muscle cell proliferation 
[15]. Moreover, Chlamydia pneumoniae seems to be able 
to impair apoptosis of infected cells leading to chronic 
infection and to induce ciliostasis in the bronchi. On the 
other hand, Mycoplasma pneumoniae attaches to and 
destroys ciliated epithelial cells of the respiratory tract 
mucosa. It induces the secretion of IL-8 and TNF-alpha 
in  vitro [16], Type-2 allergic inflammation in sensitized 
mice [17] and increased serum IL-4, IL-5 [18] and IgE 
levels in vivo [19].
As atypical bacterial infection of epithelial cells induces 
the production of a cascade of cytokines that recruit and 
activate immune cells, we wanted to evaluate if patients 
with signs of chronic infection had different inflamma-
tory phenotypes and severity profile.
Methods
Subject characteristics
We conducted a prospective study on a series of 406 
patients with asthma recruited from the University 
Asthma Clinic of Liege between 7th of June 2016 and 
26th of June 2018. The patients came from routine prac-
tice to University Hospital and were recruited by two 
clinicians involved in asthma. Entry criteria were any 
patients with asthma who accepted to undergo detailed 
investigation at the Asthma Clinic. Their demographic, 
functional and inflammatory characteristics are summa-
rised in Tables 1, 2 and 3.
Asthma was diagnosed based on the presence of 
chronic respiratory symptoms such as cough, breath-
lessness or dyspnoea together with the demonstra-
tion of airflow variability. The latter was defined by 
airway hyper-responsiveness shown by one or more of 
the following: increase in Forced Expiratory Volume in 
1  s  (FEV1) of > 12% and 200  ml following inhalation of 
400  µg salbutamol or inhaled concentration of metha-
choline provoking a 20% fall in  FEV1 of < 16  mg/ml. 
Methacholine challenge was performed according to a 
standardised methodology as previously described. Sub-
jects were characterised as atopic if they had at least one 
positive specific IgE (> 0.35 kU/l; Phadia) for at least one 
common aeroallergen (cat, dog, house dust mites, grass 
pollen, tree pollen and a mixture of moulds). Exacerba-
tion in the previous year was defined by a course of oral 
corticoids for at least 3 days in case of asthma worsening. 
Patients experiencing an exacerbation treated with OCS 
or antibiotics during the last 6 weeks were excluded.
Study design
Patients underwent FeNO measurement at a flow rate 
of 50 ml/s according to the ERS/ATS recommendations 
(NIOX, Aerocrine, Sweden). FeNO was first measured 
and followed by spirometry with bronchodilation, spu-
tum induction and blood sampling. All tests were per-
formed on the same day.
Quality of life was assessed using the self-administered 
Asthma Quality of Life Questionnaire (AQLQ) [20] and 
asthma control by the Juniper Asthma Control Question-
naire (ACQ) [21] and Asthma Control Test [22].
Sputum was induced and processed as previously 
reported and was successful in 78% of the patients 
encountered in our asthma clinic which is similar to 
previous report. Cell count were estimated on samples 
centrifuged (Cytospin) and stained with Diff Quick after 
counting 500 cells (Dade, Brussels, Belgium).
This study was conducted with the approval of the eth-
ics committee of CHU Liege.
Determination of Chlamydia pneumoniae and Mycoplasma 
pneumoniae status
Due to the difficulties of detecting the bacteria in air-
way secretions, we used indirect methods to differen-
tiate acute from possible chronic infection. Serum C. 
pneumonia-specific antibodies were detected with the 
aid of a quantitative ELISA-based assay (Savyon® kit) and 
processed with the Eti-max 3000® analyzer (DiaSorin). 
Values of IgA greater than or equal to 2 UA/ml were 
considered positive in the present study. For IgG, a cut-
off of ≥ 28 UA/ml was used. The kinetics of IgG and IgA 
secretion are taken into account when determining acute 
or chronic infection. Chronic infection diagnosis requires 
the detection of persistent serum IgG levels and persis-
tence of elevated IgA levels on two samples taken at 2 
weeks interval [23]. Patients were then separated in 3 dif-
ferent groups according to their serological results (IgA 
negative and IgG negative, IgA negative and IgG positive, 
and IgA positive and IgG positive). Asthmatics who were 
IgA positive and IgG negative (n = 4) were excluded due 
to the acute character of respiratory infection.
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Serum Mycoplasma pneumoniae antibodies were ana-
lyzed with a quantitative assay by immunoluminometric 
method, LIAISON®XL analyzer (DiaSorin). IgM were 
either positive or negative and IgG were considered posi-
tive when ≥ 11 UA/ml.
Effect of macrolides
14 asthmatics with IgA + /IgG + for Chlamydia pneumo-
niae received macrolides after the first visit at the Asthma 
Clinic due to the presence of neutrophilic asthma (spu-
tum neutrophil count ≥ 76%) insufficiently controlled 
with ICS/LABA treatment. Demographic, functional and 
inflammatory characteristics of these patients were com-
pared before and after treatment with antibiotics.
Table 1 Demographic characteristics of  asthmatics according to  the  presence of  IgG and  IgA against  Chlamydia 
pnaumoniae
Results are presented as mean + SD for categorial variables and median (IQR) for skewed distribution. *:  Significantly different from IgA-IgG-group
*: Different from IgA−/IgG−. #: Different from IgA− IgG + 
* p < 0.05
** p < 0.001
*** p < 0.0001
# p < 0.05
## p < 0.001




IgA−, IgG + 
Chlamydia pn
IgA + , IgG + 
N 145 (35.5%) 193 (47.5%) 68 (17%)
Gender (F, %) 68 63 49*##
Age (years) 47 ± 16 51 ± 17* 57.5 ± 13***#
Age of onset (years) 34 ± 22 35 ± 22 39 ± 22
Asthma duration (years) 8 (1–23) 10 (3–26) 14.5 (2.5–25)*
BMI (Kg/m2) 26.5 (22.6–29.4) 27 (23.4–30.9) 26.4 (23.3–30)
Tobacco
Smokers (%, PY) 12.4 (13 (0.3–60) 18.1 (21 (1.4–58) 19.1 (25 (4–68)
Ex-smokers (%, PY) 27.6 (9 (0.2–75) 25.9 (16 (0.8–83) 35.3 (22 (0.8–75)
Non-smokers (%) 60 56 46 *
Environment
City (%) 24 23 27
Country side (%) 38 44 47
Suburban (%) 30 26 22
Atopy (Y, %) 50 50 49
Exacerbations (n) 0.88 ± 1.70 0.86 ± 1.60 1.06 ± 2.04
Classification
Mild (%) 56 55 38*#
Moderate (%) 16 19 29*
Severe (%) 28 26 31
Dose of ICS (equivalent of beclomethasone) 760 ± 825 795 ± 1034 1022 ± 1042*
Oral corticoids (Y, %) 10 11 10
Biologics (Y, %) 5 3 0
Anti-IgE (n) 1 2 0
Anti-IL5 (n) 4 2 0
Long-term macrolides (Y, %)  2 0.5 3
Antileukotrienes (Y, %) 23 29 29
ACT 15.5 ± 5.2 15.5 ± 5.6 14.5 ± 0.7
ACQ 1.88 ± 1.16 1.99 ± 1.30 2.19 ± 1.13
AQLQ 4.61 ± 1.41 4.52 ± 1.48 4.29 ± 1.28
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Statistical analyses
The results were expressed as mean ± SD or 
mean ± SEM for continuous variables; median and 
interquartile ranges (IQR) were preferred for skewed 
distributions. For categorical variables, the number of 
observations and percentages were given in each cat-
egory. Comparisons between different subgroups were 
performed with a Kruskal–Wallis test. The Spearman 
correlation coefficient was used to measure the asso-
ciation between clinical parameters. Paired T-test were 
used to compare patients before and after treatment 
with macrolides. Variables independently associated 
to Positivity to Chlamydia (IgA−/IgG + and IgA + /
IgG +) were identified by logistic regression. Independ-
ent variables such as Age, BMI, Gender, Tobacco status, 
disease duration, post-BD  FEV1, post-BD  FEV1/FVC, 
RV/TLC, sGaw, ACQ score, AQLQ score, exacerba-
tions during the last year, FeNO, Sputum Eosinophils 
(%), Sputum neutrophils (%), Blood eosinophils (/mm3), 
Blood neutrophils (/mm3), total IgE, and ICS dose were 
included in the univariate model. Positivity to Chla-
mydia (IgA−/IgG + and IgA + /IgG +) was used as the 
dependent variable. A multivariable stepwise forward 
analysis was done including all independent variables. 
A p value < 0.05 was considered statistically significant. 
Statistical analysis was done using STATA version 14.0 
(Statistical Software, College Station, TX: StataCorp 
LP).
Table 2 Inflammatory characteristics of  asthmatics according to  the  presence of  IgG and  IgA against  Chlamydia 
pneumonia 
Results are presented as mean + SD for categorial variables and median (IQR) for skewed distribution. *:  Significantly different from IgA−IgG−group
*: Different from IgA−/IgG−. #: different from IgA−IgG + 
* p < 0.05
** p < 0.001
*** p < 0.0001
# p < 0.05
## p < 0.001




IgA−, IgG + 
Chlamydia pn
IgA + , IgG + 
N 145 (35.5%) 193 (47.5%) 68 (17%)
FeNO (ppb) 23 (16–47) 22 (12–38) 21 (14.3–34)
Blood eosino, % 2.7 (1.5–4.4) 2.5 (1.3–4.5) 2.9 (1.7–4)
Blood eosino, /mm3 187 (104–399) 181 (92–330) 191.5 (107–272)
Blood neutro, % 55.8 (49.4–62.2) 56 (48.2–62.1) 55.1 (49.2–62.1)
Blood neutro, /mm3 3881 (3291–4865) 3931 (3028–5358) 3959 (3162–4995)
Blood mono, % 7.1 (5.9–8.1) 7.7 (6.4–9.2)* 7.2 (5.8–9)
Blood mono, /mm3 492 (390–647) 572 (444–707)* 514 (401–644)
Blood lympho, % 33 (27.7–38.4) 32.2 (25.7–39.2) 32.6 (25.9–41.1)
Blood lympho, /mm3 2360 (1878–2839) 2298 (1888–2787) 2201 (1780–2777)
IgE (U/L) 74 (28–259.5) 97.5 (26.5–315) 85.5 (28–284)
Fibrinogen, g/l 3.28 (2.66–3.81) 3.32 (2.76–3.84) 3.5 (3.03–3.98)*
CRP, mg/l 2.14 (0.84–5.39) 2.53 (0.99–5.14) 2.47 (1.07–4.86)
Alpha-1-antitrypsin 1.37 (1.21–1.54) 1.43 (1.29–1.58)* 1.47 (1.31–1.58)
Cortisol, nmol/l 175 (138–295) 187 (146–271) 183 (125–268)
Sputum eosino, % 2.1 (0.35–9.6) 1.2 (0.2–4.9) 0.8 (0–3.5)*
Sputum eosino, × 103/gr 45 (2.1–170.3) 16 (0.74–116) 12.1 (0–64.4)*
Sputum neutro, % 61 (44.5–80.4) 63.6 (42.2–83.6) 69.9 (35.5–83.8)
Sputum neutro, × 103/gr 906 (350–2405) 878 (304–3543) 811.5 (294–2292)
Sputum lympho, % 1 (0.2–1.95) 1 (0.2–2) 0.8 (0–1.9)
Sputum lympho, × 103/gr 11.8 (1.65–37.7) 14.4 (2–47.3) 10.1 (0–36.7)
Sputum macro, % 20.5 (10.6–35.4) 20.3 (9.7–36.5) 17.6 (10.3–36.6)
Sputum macro, × 103/gr 311 (123–665) 363 (139–839) 263 (115–846)
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Results
406 asthmatics who underwent a visit to the asthma 
clinic in stable state with a measurement of serum IgA 
and IgG for Chlamydia pneumoniae and IgG and IgM for 
Mycoplasma pneumoniae were included in this study.
Only 12.6% of our asthmatic population had IgM 
and/or IgG against Mycoplasma pneumoniae while 
65% had IgA and/or IgG against Chlamydia pneu-
moniae (Fig.  1). Seroprevalence for C. pneumoniae 
increased with age, with antibodies detected in 50% 
of teenagers, in 62% of middle-aged adults and in 70% 
after 60  years of age. Seroprevalence for M. pneumo-
niae was high in children and teenagers then relatively 
stable across all other ages, reaching 16% in old age. 
Due to the low frequency of positive serology against 
Mycoplasma pneumoniae, we did not perform between 
subgroups statistics as it would have been difficult to 
draw any conclusions. Looking at Chlamydia pneumo-
niae history of infection, we compared three groups of 
patients classified according to the serological status. 
The first group included asthmatics without history of 
Chlamydia pneumoniae infection (IgG and IgA nega-
tive) and was used as the control group. The second 
group comprised of patients with a previous infection 
with Chlamydia pneumoniae (IgG positive but IgA 
negative). The third group involved asthmatics with 
chronic infection with Chlamydia pneumoniae (IgG 
and IgA positive).
Demographic, functional and inflammatory characteristics
Asthmatics with Chlamydia pneumoniae IgA + /
IgG + serology
Patients with chronic infection to Chlamydia pneumo-
niae were more often males, were older with a lower 
proportion of non-smokers. Most of them had moderate 
or severe asthma and were treated with higher doses of 
inhaled corticosteroids. They had a longer disease dura-
tion as compared to asthmatics without a history of 
Chlamydia pneumoniae infection. They also had lower 
 FEV1/FVC ratio and more signs of air trapping with a 
higher residual volume on total lung capacity ratio. Their 
conductance was lower and they exhibited higher fibrin-
ogen but similar C reactive protein (CRP) levels. We also 
found lower rates of sputum eosinophilic inflammation 
in these patients as compared to Chlamydia pneumoniae 
IgA−/IgG− asthmatics (Fig. 2).
Table 3 Functional characteristics of asthmatics according 
to  the  presence of  IgG and  IgA against  Chlamydia 
pneumoniae 
Results are presented as mean + SD for categorial variables and median (IQR) for 
skewed distribution. Geometric mean for PC20M. *:  Significantly different from 
IgA−IgG−group
*: Different from IgA−/IgG−. #: Different from IgA−IgG + 
* p < 0.05
** p < 0.001
*** p < 0.0001
# p < 0.05
## p < 0.001




IgA−, IgG + 
Chlamydia pn
IgA + , IgG + 
N 145 (35.5%) 193 (47.5%) 68 (17%)
Post-BD FEV1, % 91 ± 22 90 ± 21 88 ± 23
Reversibility, % 7 ± 12 6 ± 10 6 ± 9
FEV1/FVC, % 79 ± 11 78 ± 10 77 ± 12*
PC20M (mg/ml) 2.81 ± 5.70 2.75 ± 8 .02 2.10 ± 6.32
RV/TLC, % 42 ± 12 45 ± 12 48 ± 10*#
DLCO, % 79 ± 16 77 ± 18 75 ± 18
KCO 92 ± 20 90 ± 18 91 ± 20
sGaw (L/sec/kPa/L) 0.82 ± 0.37 0.81 ± 0.42 0.70 ± 0.31*
TLC, % 98 ± 15 97 ± 13 97 ± 14
FRC, % 124 ± 30 124 ± 27 130 ± 28
Fig. 1 Prevalence of positive IgA/IgG against Chlamydia pneumoniae 
(upper panel) and IgM/IgG against Mycoplasma pneumoniae (lower 
panel)
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We performed a stepwise multivariate regression anal-
ysis to highlights predictors of positive serology against 
Chlamydia pneumoniae (Table  4). Predictors of sero-
positivity to Chlamydia pneumoniae were age (OR 1.02, 
p = 0.001), gender (OR: 0.59, p = 0.015) and FeNO (OR: 
0.76, p = 0.019).
Fig. 2 Comparison of patients with Chlamydia pneumoniae IgA−/IgG−, IgA−/IgG + and IgA + /IgG + sero-status. Group 0: Chlamydia pneumoniae 
IgA−/IgG−. Group 1: Chlamydia pneumoniae IgA−/IgG + . Group 2: Chlamydia pneumoniae IgA + /IgG + 
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Asthmatics with Chlamydia pneumoniae IgA−/
IgG + serology
Patients with positive IgG but negative IgA for Chla-
mydia pneumoniae had similar demographic, clinical, 
functional and inflammatory characteristics as compared 
to those without a history of Chlamydia pneumoniae 
infection with the only differences being that they were 
older and had higher blood monocyte counts and alpha-1 
antitrypsin levels. It should be noted that both mono-
cytes and alpha-1-antitrypsin levels were within the nor-
mal range.
Asthmatics with positive serology towards Mycoplasma 
pneumoniae
Compared to the other groups, patients with chronic 
Mycoplasma pneumoniae infection were more often 
males. This was the only significant difference as com-
pared to asthmatics without history (IgM−/IgG−) or 
with previous infection (IgM−/IgG +) to Mycoplasma 
pneumoniae.
Association between IgG antibodies levels 
to Chlamydia pneumoniae and demographic, functional 
and inflammatory characteristics of asthmatics
The median IgG titer for patients with a history of Chla-
mydia pneumoniae infection was 84 (median 30 to 500) 
while IgG index was 20 (0–22) for the negative counter-
part. We found a positive correlation between the level of 
IgG against Chlamydia pneumoniae and age (p = 0.0058, 
r = 0.14), history of smoking measured in pack-years 
(p = 0.0043, r = 0.14), air trapping (residual volume on 
total lung capacity ratio (p = 0.04, r = 0.11)) and alpha-1 
antitrypsin level (p = 0.0087, r = 0.14) while there was a 
negative correlation with  FEV1/FVC ratio (p = 0.0199, 
r = − 12), post-BD  FEV1 (p = 0.04, r = − 0.10) and sGaw 
(p = 0.04, r = − 0.11).
Looking at IgA levels, we found a positive correlation 
with age (p = 0.0002, r = 0.18), age of onset (p = 0.02, 
r = 0.12), history of smoking (in pack years) (p = 0.0052, 
r = 0.14), the dose of ICS (p = 0.037, r = 0.10), asthma 
control (ACQ, p = 0.02, r = 0.12), air trapping (RV/
TLC, p = 0.006, r = 0.15)) while there was a negative 
correlation with  FEV1/FVC (p = 0.04, r = − 0.10) and dif-
fusion capacity (p = 0.047, r = − 0.11).
Effect of macrolides in a sub‑population with sputum 
neutrophilic inflammation
14 patients received macrolides after the first visit at the 
Asthma Clinic and came back 9 to 12 months later for a 
follow-up visit. After macrolides were initiated, we found 
a significant decrease in blood neutrophils (from 5225/
mm3 (2999–6627) to 2562 (2240–4692), p = 0.016) and 
a significant reduction in sputum neutrophils (from 85% 
(80–95) to 67% (29–87), p = 0.047).
Discussion
Positive Chlamydia serologic test is far more common 
than positive Mycoplasma serology. Patients with IgA 
and IgG against C. pneumoniae have more severe disease 
with increased airway obstruction, higher doses of ICS, 
more signs of air trapping and less type-2 inflammation. 
As opposed to Chlamydia pneumoniae seropositive asth-
matics, patients with a history of Mycoplasma pneumo-
niae infection in our study were infrequent and did not 
exhibit specific features.
Prevalence of seropositive patients to Chlamydia 
pneumoniae and Mycoplasma pneumoniae
In our study, we found that 65% of asthmatics had signs 
of past exposure and 17% had signs of chronic infec-
tion to Chlamydia pneumoniae. The results reported in 
the literature concerning the prevalence of Chlamydia 
pneumoniae infection in patients with asthma are con-
flicting due to various methods of measurement and IgA 
and IgG thresholds used. Our results are very close to 
those of Gencay et al. [23] who found that 63% of asth-
matics had signs of past infection (high IgG) while IgA 
was present in 52% and serological evidence of chronic 
infection (high IgG and high IgA) was detected in 18.2% 
of asthmatics. Cook et al. [24] however found only 14.6% 
of asthmatics with signs of previous infection defined as 
IgG 64–256 or IgA > 8, and this percentage was higher 
in severe asthma (35%) [24]. Hahn et al. [6] found higher 
Table 4 Multivariable stepwise forward analysis
Variables independently associated to positivity to Chlamydia (IgA−/IgG + and IgA + /IgG +)
Chlamydia Total population
Univariate Multivariable
 OR 95%CI P‑value  OR 95%CI P‑value
Age 1.02 1.01–1.03  < 0.0001 1.02 1.00–1.03 0.001
Gender (M) 0.69 0.46–1.03 0.067 0.59 0.38–0.90 0.015
FENO 0.79 0.64–0.99 0.040 0.76 0.60–0.96 0.019
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rates of exposure to Chlamydia pneumoniae, with 72% of 
asthmatics having Chlamydia pneumoniae IgA as com-
pared to 44% in the control group while 92% had IgG 
against Chlamydia pneumoniae. The median Chlamydia 
pneumoniae IgG titer reported in our study was similar 
to the one reported by Pasternack et al. [25].
As previously described in the literature, we found 
13% of patients having positive IgM and/or IgG against 
Mycoplasma pneumoniae which is clearly lower than that 
observed with Chlamydia pneumoniae. Using PCR-based 
assays, prevalence of M. pneumoniae in the lower airway 
has been reported to be 16.7 to 19.4% in a study looking 
at 310 asthmatics [26].
As compared to a general population of healthy sub-
jects [27], the prevalence of seropositivity to Chlamydia 
and Mycoplasma pneumoniae followed the same trend 
with ageing in our population of asthmatics. The pro-
portion of Chlamydia pneumoniae positive patients was 
similar in asthmatics as compared to healthy subjects 
while the percentage of Mycoplasma pneumoniae posi-
tive patients was lower in our asthmatic population as 
compared to that reported by Tuuminen et  al. [27] in 
healthy subjects. These results suggest that asthma is not 
a risk factor for infections with atypical bacteria.
Characteristics of asthmatics with Chlamydia pneumoniae 
IgA + /IgG + serology
In our study, patients with high levels of IgA and IgG 
against Chlamydia pneumoniae were more often males, 
were older and had a higher proportion of patients with 
a history of smoking. Wark et  al. [28] also compared 
patients with raised to those with not raised Chlamydia 
pneumoniae antibody titer. They however did not find 
differences in age, gender, smoking status and atopy. 
However, they used a lower threshold for IgG with a 
poor sensitivity for classification of patients in different 
groups. Factors such as male gender, age and smoking 
have been previously found to favor the establishment of 
a persistent Chlamydia pneumoniae infection [29]. Age 
and gender were also highlighted as independent predic-
tors of seropositivity to Chlamydia pneumoniae in our 
multivariate analysis. We also found a positive correla-
tion between IgG and IgA titers against Chlamydia pneu-
moniae and age. It is not surprising that IgG titers was 
correlated with ageing in our study as there is a higher 
probability to have repeated contacts with the bacteria. 
The positive correlation between IgA titers and age and 
age of onset found in our study suggests a higher risk of 
persistent infection in older patients and maybe a link 
between Chlamydia pneumoniae infection and late onset 
asthma. Moreover, ageing is associated with changes in 
immune system and could increase the risk of persis-
tent IgA against Chlamydia pneumoniae. Our results 
show that a higher history of smoking is associated with 
higher IgA and IgG titers. This might be explained by a 
decreased bacterial clearance in patients exposed to ciga-
rette smoke. Higher history of smoking could also be an 
indirect reflect of the link with ageing as pack-years natu-
rally increase with ageing.
Most of our IgA + /IgG + patients had moderate or 
severe asthma and were treated with higher doses of 
inhaled corticosteroids. Whether ICS are a cause or a 
consequence of chronic infection with Chlamydia pneu-
moniae remains to be determined. Higher doses of ICS 
may indeed modify local immune responses by reduc-
ing cytokine production in the lungs by effector T-cells 
and eosinophilia but may also negatively affect the host’s 
ability to eradicate intracellular pathogen by downregu-
lating Natural Killer cell activity and IL-12, IL-10 and 
TGF-Beta production by macrophages. Higher doses 
of ICS may however also be a consequence of poorer 
asthma control due to chronic Chlamydia pneumoniae 
infection during which Chlamydia pneumoniae enter 
a state of “latency” but are still able to synthetize heat 
shock protein 60 [11] able to induce a strong inflamma-
tory response. Previous studies have found contradic-
tory results. Black et al. [30] reported that patients with 
elevated levels of both IgA and IgG were more likely to 
require high-dose ICS and Cook et al. [24] found a higher 
rate of patients with elevated IgG and IgA titers in severe 
asthma as compared to mild to moderate asthma. Wark 
et al. [28] however did not find any difference in the dose 
of ICS in IgA + /IgG + versus IgG−/IgA− patients, but as 
previously said, this study used lower IgG threshold with 
a risk of decreased sensitivity for patients’ classification 
in different subgroups. The interaction between Chla-
mydia pneumoniae, ICS and the host’s immune system in 
asthma may thus lead to a vicious circle where increas-
ing the dose of ICS decreases local immunity and triggers 
re-activation of persistent Chlamydia to active forms of 
the intracellular bacterium. Laitinen et  al. [31] indeed 
reported that corticosteroids could reactivate Chlamydia 
pneumoniae infections in up to 60% of mice. This could 
explain why severe asthmatics, treated with higher doses 
of ICS, are more prone to be Chlamydia pneumoniae 
IgA + /IgG + . Looking at IgA levels, we found a posi-
tive correlation  with the dose of ICS suggesting a higher 
risk of persistent infection in patients treated with higher 
doses of ICS. Moreover, elevated IgA levels against Chla-
mydia pneumoniae may be an important marker of sub-
jects who are less able to clear Chlamydia pneumoniae 
[32]. Other previous studies have also reported that asth-
matics with earlier Chlamydia pneumoniae infection are 
more likely to develop steroid-resistant asthma, and air-
way neutrophilia [30, 33].
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Inflammatory and functional characteristics of asthmatics 
with Chlamydia pneumoniae IgA + /IgG + serology
In our study, asthmatics in stable state with chronic Chla-
mydia pneumoniae also displayed lower eosinophilic 
airway inflammation. Though immune response dysreg-
ulation from C. pneumoniae with predominant Type-2 
response has been described in the bacterial allergy 
model for asthma pathogenesis [34], chronic infection 
with C. pneumoniae in severe asthma has been linked 
to exaggerated Th1/Th17 responses and neutrophilic 
inflammation in  vitro [35]. Wark et  al. [28] found that 
patients positive for Chlamydia pneumoniae had signifi-
cantly more sputum neutrophils (4.6 × 106 C/mL) and 
monocytes during acute asthma with Chlamydia pneu-
moniae infection, but no significant differences in spu-
tum cell count was found one month after acute infection 
between those who had antibodies and those who had 
not. In our study, no association was found between 
chronic infection and sputum neutrophil counts. We 
however observed significantly lower sputum eosinophil 
counts in patients with a serologic signature of Chla-
mydia pneumoniae infection. It could be suggested that 
the decrease in sputum eosinophils observed in asthmat-
ics with persistent IgA and IgG against Chlamydia pneu-
moniae might be due to treatment with higher doses of 
ICS in this subgroup. When focusing on the steroid naïve 
patients (n = 145) included in our study, we however con-
firm lower numbers of sputum eosinophils in asthmat-
ics with IgA + /IgG + against Chlamydia pneumoniae 
(0.6 (0–1.6)) as compared to IgA−/IgG− (1.4 (0.4–4.2), 
p < 0.05). Additionally, no association was found with IgE, 
as it has been previously reported [12].
In our population, IgA + /IgG + patients with asthma 
had lower  FEV1/FVC ratio and sGAW indicating more 
severe airway obstruction and more signs of air trap-
ping with a higher residual volume on total lung capac-
ity ratio. It might be that the lower  FEV1/FVC and higher 
RV/TLC observed in this Chlamydia pneumoniae IgA + /
IgG + asthmatics is a consequence of the older age of this 
subgroup. We indeed recently demonstrated that elderly 
asthmatics had higher RV/TLC and lower  FEV1/FVC 
[36]. We found a positive correlation between IgG titers 
against Chlamydia pneumoniae and measure of air trap-
ping while there was a negative correlation with  FEV1/
FVC, post-BD  FEV1 and sGaw.
Ten Brincke et al. [37] previously showed that patients 
with IgG antibodies had a fourfold greater decline in 
post-BD FEV1/FVC ratio as compared with patients 
without elevated titers of IgG. This suggests that the res-
piratory pathogen might be involved in airway remod-
eling. Pasternack et al. found that adults with nonatopic 
asthma with chronic Chlamydia pneumoniae infection 
had a faster decline in  FEV1 [25]. We found elevated RV/
TLC ratio in IgA + /IgG + patients. A small study con-
ducted by Weiss et al. [38] in a population of children also 
found signs of elevated trapped air after Chlamydia pneu-
moniae infection. Our study is the first attempt to look at 
air trapping in adult IgA + /IgG + patients with asthma in 
stable state. We found signs of air trapping suggestive of 
distal airway dysfunction in patients with chronic infec-
tion with Chlamydia pneumoniae. This might be due to 
remodeling induced by chronic infection with this intra-
cellular bacterium. We are the first to report a decreased 
conductance in IgA + /IgG + patients with asthma, an 
indirect sign of increased bronchial hyperresponsiveness.
Even if we found an increased fibrinogen level in the 
IgA + /IgG + asthmatics, this level remained within the 
normal range. This may reflect the low grade chronic 
inflammation induced by the persistence of intracellular 
Chlamydia pneumoniae.
Asthmatics with serologic signature of Mycoplasma 
pneumoniae infection
As opposed to Chlamydia pneumoniae seropositive asth-
matics, patients with a history of Mycoplasma pneumo-
niae infection were not frequent in our study and did not 
exhibit specific features. This is in line with the findings 
of Ansarin et  al. who reported no difference in asthma 
control and lung function tests between asthmatics with 
and without evidence of chronic Mycoplasma pneumo-
niae infection [39].
Effect of macrolides in a sub‑population with sputum 
neutrophilic inflammation
The more frequent type-1 inflammation observed in 
Chlamydia pneumoniae IgA + /IgG + asthmatics has led 
to consider treatment of atypical infections as an aspect 
of the management of asthma patients. Recent studies 
have evaluated the benefits of using macrolides in asthma 
and have shown improvement in symptoms and reduc-
tion of exacerbations [40]. In patients serologically posi-
tive for atypical bacteria, improved lung function [41] 
and asthma control [42] have been demonstrated with 
macrolides.
Macrolide mechanisms of action in asthma are thought 
to be directly anti-inflammatory or indirectly anti-
inflammatory with an anti-microbial against chronic 
atypical infections [10]. A pre-existing chronic  Chla-
mydia pneumoniae  lung infections could indeed explain 
the effect of macrolides in asthma [43]. Kraft et  al. [41] 
reported clinical improvements with clarithromycin in 
asthmatics PCR-positive for Chlamydia pneumoniae and 
Mycoplasma pneumoniae but this was not confirmed by 
other groups [42, 44].
In our study, 14 patients IgA and IgG positive against 
Chlamydia pneumoniae received macrolides after the 
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first visit at the Asthma Clinic for neutrophilic asthma 
insufficiently controlled with ICS/LABA treatment. 
Patients came back 9 to 12 months later for a follow-up 
visit. We found a significant decrease in blood neutro-
phils and a significant reduction in sputum neutrophils 
after treatment with macrolides. Previous trials have 
found an improvement in  FEV1 value after antibiotic 
treatment. Like the study of Gibson et  al.[45], we did 
not find a significant change in lung function tests after 
treatment in our small cohort. We found a reduction in 
exacerbation rate after treatment with macrolides that 
however remained nonsignificant (0.33 ± 0.5 versus 
0.11 ± 0.33, p = 0.34). Previous studies have suggested a 
beneficial effect of macrolides in neutrophilic asthma [40, 
45]. In our study focusing on hyperneutrophilic patients, 
we found a reduction in sputum neutrophils from 85 to 
67% (p < 0.05). Gibson did not find a significant reduction 
in sputum neutrophils but median neutrophil count was 
34% in patients receiving azithromycin. Our study goes 
further, indicating that treating patients with Chlamydia 
pneumoniae IgA + /IgG + and sputum neutrophils ≥ 76% 
with macrolides may allow a normalization of bronchial 
neutrophilic inflammation. Concerns about adverse 
effects of macrolides however include development of 
antibiotic resistance.
Study limitation
A potential limitation of the present study is that infec-
tion with Chlamydia pneumoniae and Mycoplasma 
pneumoniae have been inferred serologically without 
isolation of organism. Chlamydia pneumoniae and Myco-
plasma pneumoniae are however difficult to culture. 
We used IgA and IgG measurement for identification of 
chronic infection without the detection of Chlamydia 
pneumoniae mRNA within tissue and cell types by PCR. 
Direct methods such as mRNA detection can establish 
the presence of the pathogen and perhaps its viability. 
The sensitivity is however limited due to low copy num-
bers or sampling problems due to deep tissue intracel-
lular location for this species. Therefore seroreactivity is 
valuable to differentiate acute from chronic infection.
Conclusion
Chlamydia serologic test is more often positive than 
Mycoplasma serology in asthmatics. Patients with ele-
vated levels of IgA and IgG against C. pneumoniae have 
more severe disease with increased airway obstruction, 
higher doses of ICS, more signs of air trapping and less 
type-2 inflammation.  As opposed to Chlamydia pneu-
moniae seropositive asthmatics, patients with a history 
of Mycoplasma pneumoniae infection did not exhibit 
specific features. Treatment of Chlamydia pneumoniae 
seropositive neutrophilic asthmatics with macrolides sig-
nificantly decrease sputum and blood neutrophils.
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